Abstract
Introduction
The occurrence of non-thyroidal second primary malignancy (NTSPM) in patients with papillary thyroid cancer (PTC) is well documented, but epidemiological data are conflicting.
Objective
The aim of this study was to evaluate the incidence of NTSPM in a large series of patients with PTC and to assess its potential risk factors.
Methods
Single-center cohort study with retrospective data collection conducted on consecutive PTC patients diagnosed from 1988 to 2018 with a minimum follow-up time of 2 years. NTSPM was defined as any primary malignancy with histological confirmation occurring in an anatomical site other than the thyroid. According to the timing of occurrence, NTSPM were subdivided into anachronous, synchronous or metachronous (diagnosed >6 months before, within 6 months and >6 months after PTC diagnosis, respectively).
Results
We included 773 individuals (83.3% females), median age at PTC diagnosis was 47.0 (IQR: 37.0–58.0) years and median follow-up time was 9.9 (6.2–16.3) years. Incidence of NTSPM was 15.5% (n = 120) and its standard incidence ratio (SIR) was higher when compared to the general population (SIR: 2.70). Family history of malignancy and younger age at diagnosis were associated respectively with 206 and 4% increased risk of developing metachronous neoplasia (HR: 2.06 (95% CI: 1.10–3.86) and 1.04 (95% CI: 1.02–1.05), respectively).
Conclusion
In our series, the occurrence of NTSPM was not uncommon and its incidence was higher compared to the general population. First-degree family history of malignancy was a strong risk factor for multiple primary malignancies.
Introduction
Differentiated thyroid carcinoma (DTC) is the most common endocrine gland malignancy, most frequently diagnosed among women between the ages of 45 and 54 years (1, 2). Despite the increasing incidence worldwide over the last years, thyroid cancer has an excellent prognosis with a 5-year disease-specific survival rate of over 95% (2).
Increased risk of non-thyroidal second primary malignancy (NTSPM) in DTC patients has been reported in several cancer epidemiological and registry studies (3, 4, 5, 6, 7, 8, 9, 10, 11). These individuals can present anachronous (antecedent), synchronous or metachronous NTSPM with a reported frequency ranging between 1 and 19% (3, 5, 6, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23). This wide variability may reflect the conflicting methodology and different populations, with the best evidence emerging from population-based cancer registries (5, 6, 8, 9, 23) or multinational studies (7, 10).
There is a long experience in the use of radioiodine for diagnostic and therapeutic purposes in thyroid pathology (24). Particularly, in DTC, radioiodine ablation after surgery can be recommended, according to the risk assessment, in order to eliminate residual normal or neoplastic thyroid tissue (24). Despite its safety, its use is not without risks. The most frequent adverse effects are mild and limited to time (e.g. nausea and sialadenitis) (23), but a potential carcinogenic effect is a long-term negative effect that has been described (3, 5, 11, 21, 23).
Studies about this topic in the Portuguese population are very scarce. A paper by Silva-Vieira et al. (3), in a cancer registry-based analysis of the South-Portuguese population, has found an increase in the risk of NTSPM (standardized incident ratio (SIR): 1.40) in papillary thyroid carcinoma (PTC) patients submitted to radioiodine ablation.
The primary aim of this study was to evaluate the incidence of NTSPM in a series of patients with PTC at our institution. Secondary aims were to assess the relative risk for NTSPM in PTC patients and its potential associated factors, namely, radioiodine therapy exposure.
Methods
Study design
A single-center population study with retrospective data collection was conducted using PTC patients followed at our institution. Consecutive patients from 1988 to 2018 with a minimum follow-up of 2 years and at least one thyroid cancer outpatient visit between January 2018 and December 2020 were selected. Patients with insufficient or missing relevant data were excluded. The study protocol was approved by the Ethics Committee at the authors’ institution (study authorization 2021.052-042-DEFI/043-CE). Patient consent was waived by the Ethics Committee due to the retrospective nature of the study and full data anonymization.
Data collection
Demographic, clinical, anatomopathological and therapy management (radioiodine therapy (RAIT), date, number of treatments and total cumulative activity administered), as well as personal and family history of malignancy (defined as a history of malignancy in a first-degree relative) data, were retrieved from clinical records. Diagnosis of NTSPM was searched through institution clinical records and using the Portuguese Electronic Health Registry, a digital platform that merges clinical data and medical care contact (Public National Health Service with primary care and national public hospitals) for each patient. Electronic Health Registry and Primary Care data were used to determine the causes of death.
Papillary thyroid cancer treatment and follow-up
All patients underwent surgical treatment (total thyroidectomy or totalization of previous sub-total thyroidectomy) with prophylactic central compartment lymph node dissection with further lateral lymph node compartments’ exploration based on loco-regional disease assessed by pre-operative cervical ultrasound. After surgery, levothyroxine therapy was started, and according to the risk and treatment response, some patients received RAI ablation treatment.
At our institution, the criteria for RAIT became more restrictive over time. More recently, it is reserved for remnant ablation in patients with high risk of local recurrence (based on the ATA Guidelines (24)) or to treat persistent disease. Patients were considered for RAIT 6 months after thyroidectomy with levothyroxine withdrawal or recombinant thyroid-stimulating hormone stimulation. The initial activity of RAI administered ranges from 50 to 150 mCi (1850–5550 MBq), depending on risk stratification with subsequent 131I treatments performed, with a minimum 6-month interval, based on structural or biochemical evidence of disease. In the whole cohort, the total cumulative activity ranged from 50 to 750 mCi (1850–27,750 MBq).
For cohort analysis, several subgroups were considered, based on the presence or absence of RAI treatment (RAIT+ vs RAIT−, respectively), NTSPM occurrence and timing.
NTSPM definition
NTSPM was defined as any primary malignancy with histological confirmation occurring outside the thyroid gland. According to the timing of NTSPM occurrence with respect to PTC diagnosis, we subdivided NTSPM group into anachronous (diagnosed up to 6 months before PTC diagnosis), synchronous (within 6 months of PTC diagnosis) or metachronous (diagnosed more than 6 months after PTC). For patients who developed more than one NTSPM, the date of the earliest occurring malignancy were considered.
Statistical analysis
For descriptive analysis, variables were presented as mean ± s.d. or median (interquartile range) according to normal or non-normal distribution. Categorical data were presented as n (%). We used independent t-test or the non-parametric Mann–Whitney test to analyse differences between two independent subgroups. The Pearson’s chi-square test was used to evaluate differences in counts and frequency between groups for categorical variables.
Kaplan–Meyer ‘time to event’ method was used to generate the curves of cumulative incidence of NTSPM. Log-rank test was performed to test the difference between cumulative incidence and survival curves. To control for the potential confounding factors, multivariable analysis was conducted using the Cox proportional hazards model and the Fine and Gray regression model (25) for competing risk analysis to calculate the relative risk for the risk factors for NTSPM development. Results will be presented as hazard ratios (HRs) with 95% CIs. A P value <0.05 was considered statistically significant.
The incidence of NTSPM in the cohort and in both RAIT+ and RAIT− subgroups was compared with that of the general Portuguese population by calculating the standardized incidence ratios (SIRs) for all sites NTSPM (26). The SIR is the ratio of observed to expected cases in which the expected number is calculated for a reference cohort of identical age and gender. Portuguese National Oncology Registry (26) was used to retrieve the expected cases of malignancies, during the person-years at risk, on the basis of sex and age.
The statistical analysis was performed using SPSS Statistics for Windows, version 23.0 (2015, IBM Corp) and STATA Statistical Software, version 17.0 (2021, StataCorp).
Results
Patient characterization
Among the 773 individuals with PTC included in the analysis, 83.3% (n = 644) were females. Median (interquartile range) age at PTC diagnosis was 47.0 (37.0–58.0) years. Median tumour size was 12.0 (7.0–20.0) mm, and 95.0% (n = 734) of the patients underwent total thyroidectomy. First-degree family history of malignancy was present in 137 (27.4%) of the 500 individuals with available information. Over a median follow-up time of 9.9 (6.2–16.3) years, there were 21 deaths, where 0.3% (2/773) were related to PTC. Other clinical characteristics of the study group are shown in Table 1.
Clinical and pathological features of the cohort.
| Total (n = 773) | |
|---|---|
| Female sex (n, %) | 644 (83.3) |
| Age at PTC diagnosis (years) | 47.0 (37.0–58.0) |
| Tumour size (mm) | 12.0 (7.0–20.0) |
| Tumour size ≤10 mm (n, %) | 328 (42.4) |
| Type of surgery (n, %) | |
| 734 (95.0) | |
| 38 (4.9) | |
| 1 (0.1) | |
| Radioiodine treatment (n, %) | 378 (48.9) |
| Radioiodine cumulative activity (categories of mCi) | |
| <100 | 77/378 (20.4) |
| 194/378 (51.3) | |
| >100 | 107/378 (28.3) |
| First-degree family history of malignancy (n, %) | 137/500 (27.4) |
| Follow-up (years) | 9.9 (6.2–16.3) |
| PTC treatment response status at last follow-up (n, %) | |
| 574 (74.3) | |
| 33 (4.3) | |
| 20 (2.6) | |
| 145 (18.8) | |
| Overall mortality (n, %) | 21 (2.7) |
| Causes of mortality | |
| 2/21 (9.5) | |
| 7/21 (33.3) | |
| 12/21 (57.1) |
NTSPM, non-thyroidal second primary malignancy; PTC, papillary thyroid cancer.
Regarding radioiodine therapy, 48.9% (n = 378) of the patients underwent at least one treatment with a median cumulative activity administered of 100.0 (100.0–150.0) mCi. More than half of the patients in the RAIT+ group were treated with a total cumulative activity up to 100 mCi, and 28.3% (n = 107) were treated with higher activities. In the RAIT+ group, patients were significantly younger at PTC diagnosis and presented larger tumours and longer follow-up time, compared to individuals not submitted to RAIT (Table 2). Family history of malignancy (25.8% vs 28.8%, P = 0.44) was similar in both RAIT+ and RAIT− groups (Table 2).
Patients and tumour characteristics according to radioiodine treatment.
| 131I treatment (RAIT+) (n = 378) | No 131I treatment (RAIT−) (n = 395) | P - value | |
|---|---|---|---|
| Female sex (n, %) | 301 (79.6) | 343 (86.8) | 0.007 |
| Age at diagnosis (years) | 44.0 (33.0–55.3) | 49.0 (39.0–60.0) | <0.001 |
| Tumour size (mm) | 18.0 (11.0–30.0) | 9.0 (4.0–14.0) | <0.001 |
| First-degree family history of malignancy (n, %) | 60/233 (25.8) | 77/267 (28.8) | 0.44 |
| All NTSPM (n, %) | 55 (14.6) | 65 (16.5) | 0.46 |
| Metachronous only (n, %) | 40/55 | 38/65 | 0.24 |
| Age at NTSPM (years) | 56.0 (45.0–64.0) | 55.0 (46.5–64.0) | 0.78 |
| Follow-up (years) | 11.4 (7.1–20.1) | 8.8 (5.3–14.6) | <0.001 |
NTSPM, non-thyroidal second primary malignancy.
Non-thyroidal second primary malignancy
A total of 134 non-thyroidal second primary malignancy (NTSPM) were observed in 120 patients. The overall incidence of NTSPM was 15.5% (120/773) with similar rates in RAIT+ and RAIT− patients (14.6% vs 16.5%, P = 0.46). When we observed the timing of the NTSPM occurrence compared with PTC diagnosis, of the 134 NTSPM, 29.9% (n = 40) were anachronous, 5.0% (n = 7) were synchronous and 64.9% (n = 87) were metachronous. Twelve patients (12/120, 10.0%) had two or more NTSPM; therefore, the total number of malignancies is higher than the number of patients.
In the group of patients with NTSPM, PTC diagnosis was made later in life (49.0 (40.0–61.8) years vs 47.0 (36.0–57.0) years, P = 0.009) and overall mortality was significantly increased (10.8% vs 1.2%, P < 0.001 ) when compared to the group of patients with no NTSPM. Although there was no difference concerning the proportion of patients submitted to RAIT, patients with an NTSPM had been submitted to higher 131I cumulative activities (43.6% vs 25.7% treated with more than 100 mCi, P = 0.008). There was also a trend for more frequent first-degree family history of malignancy in patients with an NTSPM (34.9% vs 25.8%, P = 0.09), but it did not reach statistical significance (Table 3).
Patients and tumour characteristics according to occurrence of NTSPM.
| Patients with NTSPM (n = 120) | Patients with no NTSPM (n = 653) | P-value | |
|---|---|---|---|
| Female sex (n, %) | 96 (80.0) | 548 (83.9) | 0.18 |
| Age at PTC diagnosis (years) | 49.0 (40.0–61.8) | 47.0 (36.0–57.0) | 0.009 |
| Tumour size (mm) | 12.0 (7.0–21.5) | 12.0 (8.0–20.0) | 0.68 |
| Tumour size ≤10 mm (n, %) | 56 (46.7) | 272 (41.7) | 0.31 |
| Type of surgery (n, %) | 0.17 | ||
| 117 (97.5) | 617 (94.5) | ||
| 3 (2.5) | 35 (5.4) | ||
| – | 1 (0.2) | ||
| Radioiodine treatment (n, %) | 55 (45.8) | 323 (49.5) | 0.47 |
| Radioiodine cumulative activity (categories of mCi) | 0.008 | ||
| <100 | 5/55 (9.1) | 72/323 (22.3) | |
| 26/55 (47.3) | 168/323 (52.0) | ||
| >100 | 24/55 (43.6) | 83/323 (25.7) | |
| First-degree family history of malignancy (n, %) | 30/86 (34.9) | 107/414 (25.8) | 0.09 |
| Follow-up(years) | 11.2 (6.7–19.9) | 9.8 (6.1–15.9) | 0.17 |
| PTC treatment response status at last follow-up (n, %) | 0.06 | ||
| 97 (80.8) | 477 (73.0) | ||
| 4 (3.3) | 29 (4.4) | ||
| 6 (5.0) | 14 (2.1) | ||
| 13 (10.8) | 132 (20.2) | ||
| Overall mortality (n, %) | 13 (10.8) | 8 (1.2) | <0.001 |
| Causes of mortality | 0.008 | ||
| 2/13 (15.4) | – | ||
| 7/13 (53.8) | – | ||
| 4/13 (30.8) | 8/8 (100) |
NTSPM, non-thyroidal second primary malignancy; PTC, papillary thyroid cancer.
The most frequent second tumours were breast, colon–rectal and skin cancer. The site and prevalence of the distinct NTSPM are shown, by timing of occurrence, in Supplementary Table 1 (see section on supplementary materials given at the end of this article).
Metachronous NTSPM and potential risk factors
Like the whole group of patients with NTSPM, individuals with a metachronous NTSPM were more frequently treated with 131I cumulative activities superior to 100 mCi and presented increased mortality when compared to those without an NTSPM; additionally, a longer follow-up period was observed (14.8 (8.7–21.6) years vs 9.8 (6.1–15.9) years in the group with no NTSPM, P = 0.004), as shown in Supplementary Table 2.
We performed a sub-analysis of the individuals with metachronous neoplasia, regarding 131I exposure (Table 4). In this sample, there were 40 individuals (42 malignancies) treated with RAIT and 38 individuals (40 malignancies) not submitted to RAIT. There were no differences between groups regarding sex, age at PTC diagnosis or latency time between PTC and NTSPM diagnosis. The only significant difference between groups was the duration of follow-up, with a longer period in the RAIT group.
Individuals with metachronous neoplasia and relation to RAIT.
| Metachronous neoplasia with RAIT (n = 40) | Metachronous neoplasia with no RAIT (n = 38) | P-value | |
|---|---|---|---|
| Female sex (n, %) | 31 (77.5) | 34 (89.5) | 0.16 |
| Age at diagnosis (years) | 44.0 (34.5–55.6) | 48.5 (40.0–61.3) | 0.08 |
| Age at NTSPM diagnosis (years) | 56.1 ± 14.9 | 59.4 ± 13.3 | 0.31 |
| Latency period to NTSPM (years) | 10.1 (4.8–17.3) | 6.7 (3.1–12.8) | 0.06 |
| First-degree family history of malignancy (n, %) | 7 (29.2)a | 9 (30.0)b | 0.95 |
| Follow-up time (years) |
18.7 (11.5–25.9) | 10.8 (7.7–19.0) | 0.002 |
| Overall mortality (n, %) | 4 (10.0) | 5 (13.2) | 0.66 |
| Causes of mortality (n, %) | |||
| 1(2.5) | – | ||
| 1(2.5) | – | ||
| 2 (5.0) | 5 (13.2) | 0.20 |
a24 individuals with available information; b30 individuals with available information.
NTSPM, non-thyroidal second primary malignancy; PTC, papillary thyroid cancer.
The results of the multivariable analysis exploring the association between RAIT, first-degree family history of malignancy and metachronous NTSPM are presented in Table 5. In Fine and Gray model, adjusted for sex, with death treated as a competitive event, family history of malignancy was associated with a 206% increase in the hazard risk of metachronous NTSPM (HR: 2.06, 95% CI: 1.10–3.86, P = 0.02). Younger age at PTC diagnosis was also associated with a higher risk of metachronous NTSPM with a 4% risk increase at each additional year (HR: 1.04, (95% CI: 1.02–1.05), P < 0.001). In contrast, we did not find an increased risk associated to RAIT or to total 131I cumulative activity – data not shown.
Association between radioiodine treatment, family history of malignancy and metachronous NTSPM, controlling for age and sex.
| Covariates | Cox regression model (no competitive risk) | Fine and Gray regression model (competitive risk) | ||||
|---|---|---|---|---|---|---|
| Relative risk | 95% CI | P-value | Relative risk | 95% CI | P-value | |
| Sex | ||||||
| 1.47 | 0.66–3.31 | 0.35 | 1.41 | 0.67–2.97 | 0.36 | |
| Age at PTC diagnosis | ||||||
| 1.05 | 1.03–1.07 | <0.001 | 1.04 | 1.02–1.05 | <0.001 | |
| First-degree family history of malignancy | ||||||
| 2.11 | 1.14–3.90 | 0.02 | 2.06 | 1.10–3.86 | 0.02 | |
| RAIT | ||||||
| 0.73 | 0.41–1.28 | 0.27 | 0.72 | 0.42–1.26 | 0.25 | |
RAIT, radioiodine therapy; PTC, papillary thyroid cancer.
NTSPM in patients with PTC and RAIT
Figure 1 shows the cumulative incidence of NTSPM in the RAIT+ and RAIT− groups. The 5-year cumulative incidence rates in the RAIT+ and RAIT− groups were 3.0% (95% CI: 1.6−5.4%) and 3.8% (95% CI: 2.2−6.3%), respectively. The 10-year cumulative incidence rates were 5.5% (95% CI: 3.6−8.4%) and 6.8% (95% CI: 4.6−10.0%), respectively, in the RAIT+ and RAIT− groups. Neither statistically significant difference was found between the two groups nor when total radioiodine cumulative administered activity was considered.
Cumulative incidence of metachronous NTSPM (patients with a first antecedent neoplasia (n = 35) or with a synchronous neoplasia (n = 7) were excluded from this analysis), according to RAIT.
Citation: European Thyroid Journal 11, 4; 10.1530/ETJ-22-0018
SIR of NTSPM
The SIR of NTSPM was higher in the whole PTC group compared to the general population (SIR: 2.70 (95% CI: 2.58–2.82), P < 0.001) (Table 6). There was also a difference between the RAIT+ (SIR: 1.57 (1.48–1.66), P = 0.01) and RAIT− (SIR: 1.74 (1.65–1.84), P = 0.002) groups and the general population.
Standardized incidence ratio of NTSPM.
| Comparison of the incidence of NTSPM | Standardized incidence ratio | CI | P-value |
|---|---|---|---|
| All PTC patients vs general population | 2.70 | 2.58–2.82 | <0.001 |
| RAIT+ patients vs general population | 1.57 | 1.48–1.66 | 0.01 |
| RAIT− patients vs general population | 1.74 | 1.65–1.84 | 0.002 |
PTC, papillary thyroid cancer; RAIT, radioiodine therapy.
Overall survival
The overall 10-, 20- and 30-year survival rate for all PTC patients in our study was respectively 98.1, 95.9 and 90.7% with a mean (±s.d.) survival of 37.2 ± 0.5 years.
As shown in Fig. 2, the mean survival in patients with PTC who developed an NTSPM was significantly inferior to the group of patients with only PTC (32.0 ± 1.2 (28.8–35.3) years vs 38.4 ± 0.3 (37.9–38.9) years, P < 0.001). The increase in mortality risk in patients with NTSPM was nearly 13-fold (HR: 12.5, 95% CI: (5.2–30.4), P < 0.001); further adjustment for age and sex was made but had little effect on the HR (HR: 12.5, 95% CI: (5.1–30.2), P < 0.001).
Survival curves of patients with PTC and a NTSPM.
Citation: European Thyroid Journal 11, 4; 10.1530/ETJ-22-0018
Discussion
A retrospective cohort study was conducted to investigate the incidence of NTSPM in patients with PTC, including 773 individuals with a median follow-up time of 10 years. Approximately, 16% of PTC patients were diagnosed with another primary malignancy either prior, simultaneously or more frequently, after PTC detection. According to our data, the incidence of NTSPM in our PTC patient population was higher when compared to the general Portuguese population. First-degree family history of malignancy and younger age at PTC diagnosis, but not RAIT exposure, were associated with higher risk of metachronous NTSPM.
Published studies on the prevalence of NTSPM in thyroid cancer cohorts mostly consider papillary, follicular and medullary thyroid cancer as a whole group. The prevalence of NTSPM in these patients ranges from 1 to 19% (3, 5, 6, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23), with most studies reporting from cross-matched local and national cancer registries where demographic and personal and family history data as well as the percentage of PTC patients included are not consistently available. Our findings were within the reported range, although it includes solely PTC patients. It is possible that previously published studies may even underestimate NTSPM prevalence by including patients with lower expected survival, namely, the ones with medullary thyroid carcinoma and by excluding antecedent or synchronous malignancies.
In our paper, we also explored the possibility of a relationship between NTSPM and RAIT exposure. Although the group of patients with metachronous NTSPM were treated with significantly higher 131I cumulative doses (vs patients with no metachronous NTSPM), there was no difference in the observed cumulative incidence between the two groups (even when total 131I cumulative activity was considered). There was a longer follow-up in the RAIT group, which may be explained by their high-risk disease, and the RAIT was also not associated to an increased risk of metachronous NTSPM. Published studies on the influence of RAIT in the development of NTSPM have shown conflicting data. Similar to our observation, some authors (12, 17, 18, 20, 27, 28, 29) have observed no association between RAIT and NTSPM. With comparable follow-up times, Hirsch et al. (12) and Cappagli et al. (20) neither find an association between RAIT and an increased risk in NTSPM nor a dose–response relationship. The population in both studies, like ours, was mostly low-risk DTC patients in whom limited amplitudes of 131I activity were administered (40–60% of the patients treated with 131I total cumulative activity ≤ 100 mCi). On the other hand, previous studies (3, 5, 11, 21, 23) reported an increased incidence of NTSPM in DTC patients submitted to RAIT. A study in a south-country Portuguese population (3) found a trend for cumulative incidence of NTSPM with higher RAIT activities with statistical significance reached for activities superior to 200 mCi. It is important to highlight that our median 131I total cumulative activity was lower (100 (100–150) mCi) when compared to the proposed published 131I cumulative activity cutoffs associated with risk of NTSPM, ranging from 150 to 540 mCi (3, 11, 21).
It has often been discussed that other factors besides RAIT can be associated with NSTPM in PTC patients. Factors like sex (11, 28), age at PTC diagnosis (4, 5, 11, 17, 28) or genetics (5, 7, 18) could be related to the overall risk of NSTPM in this population. We found a two-fold increase in the risk of metachronous NTSPM in PTC patients with family history of neoplasia in a first-degree relative, as well as a significant increase in the risk in patients with younger age at PTC diagnosis. Concerning age at PTC diagnosis, Brown (5), Teng (11) and Berthe et al. (30) found an increased overall risk of second primary malignancy in patients with PTC diagnosed from ages 25–40 years old. Conversely, in the study by Lang et al. (4), age at PTC diagnosis ≥50 years emerged as an independent risk factor for the development of NTSPM. Our findings may suggest that a PTC diagnosis earlier in life might reflect a potential genetic predisposition (with consequent higher risk for developing malignancies with each passing year); a surveillance bias in this context, with more frequent screenings, may also apply. In this regard, some authors have suggested the role of certain genes in increasing the susceptibility to multiple primary malignancies development and specific association with DTC. Checkpoint kinase 2 (CHEK2) (31), RET, BRAF, RAS, PTEN and mismatch–gene repair mutations as seen in Lynch Syndrome (32) have been described as increasing the risk of a second malignancy. Concerning first-degree family history of neoplasia, to the best of our knowledge, our work is the first to point up its role as a predictor of NTSPM incidence. In our study, 30% of the NTSPM were diagnosed prior to the diagnosis of PTC. This raises the possibility of a putatively shared genetic or environmental risk factors, namely, undiagnosed hereditary cancer syndromes or susceptibility, that add on to the increased risk of cancer found in these patients.
Regarding NTSPM sites, breast, colon–rectal and skin were the most frequently affected sites with no difference in site distribution or incidence found when RAIT was considered. This tumour site distribution was also frequently reported in other DTC populations (3, 7, 12, 18, 20). A bidirectional relationship between thyroid and breast cancer has been long recognized (33) with strong evidence of a relationship between the two as survivors of either cancer are at increased risk for the development of both tumors when compared with the general population (34). Many driver mutations are similar in both cancers, and the most studied is Cowden syndrome, associated with PTEN mutations (34); additionally, germline mutations in PARP4 and CHEK2 (35) were also identified in women treated for both cancers (36). Regarding colon–rectal cancer, aberrantly methylated RET, a well-established oncogene in thyroid cancer, has been identified in colon–rectal cancers and this might explain the link between the two tumours (37). Finally, a high rate of BRAFV600E mutational background in both thyroid cancer and melanoma unravels a possible common genetic pathway in the pathogenesis of these cancers (38).
Regarding population SIR for cancer, our findings are similar to the study of Silva-Vieira et al. (3) that observed an increased risk of NTSPM in the DTC patient’s cohort (SIR: 1.32 (95% CI: 1.10–1.57)) when compared to the general population. However, while in their work there was a higher incidence of NTSPM only in the RAIT+ group (SIR: 1.40 (1.15–1.69)), our study found an increased incidence in both RAIT+ and RAIT− groups. This observation was further validated by the multivariable analysis that found no role for RAIT in the development of NTSPM and rather highlighted the importance of family history of malignancy. Regional variability and a higher 131I cumulative activity in Silva-Vieira cohort may explain the observed differences concerning the incidence of NTSPM and RAI treatment status.
Concerning survival, PTC patients with at least one NTSPM had a significantly lower mean survival when compared to patients with no NTSPM during follow-up. Confirming that PTC has a very good prognosis, mortality in this group was also exclusively associated with the non-thyroid primary malignancy. Although few studies have explored survival in PTC patients with NTSPM, all have shown that survival outcomes were higher in the group with only PTC when compared to PTC patients who developed a NTSPM (6, 14, 15).
The retrospective nature of our study and the bias associated with a single-center study are its main limitations. Other potential confounders (occupational radiation exposure, smoking habits and comorbidities) were not available, and missing data concerning family history of malignancy in 273 patients could also underpower our conclusions. On the other hand, a surveillance bias may be present as patients with a previous malignancy may be more likely to seek routine medical care. Additionally, high-risk patients are submitted to longer follow-up periods, and therefore, NTSPM is more prone to be recognized in these patients.
In conclusion, our work explored the incidence of NTSPM and its risk factors in a fairly large series of PTC patients with a median follow-up time of 10 years at the same institution, assuring clinical continuity and coherence in patients’ treatment. Furthermore, our comprehensive retrieval of information guarantees that any second primary malignancy diagnosed in Portuguese health centers was included in the analysis, data that could be missed when national cancer registries are used. To the best of our knowledge, this is the first single institution report that evaluated NTSPM in a Portuguese PTC patients’ cohort and second only to the cancer registry-based analysis of Silva-Vieira et al. Our work has shown that although the incidence of NTSPM in PTC survivors is not uncommon, the risk of subsequent malignancies is higher when compared to the Portuguese general population and that radioiodine treatment was not associated with increased risk of NTSPM. Patients’ genetic background, accessed by cancer family history, was raised as a potential risk factor to be further studied in the development of a multiple primary malignancies in PTC patients.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/ETJ-22-0018.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Statement of ethics
This study protocol was reviewed and approved by the Ethics Committee at the authors’ institution (study authorization 2021.052-042-DEFI/043-CE) and written patient consent was waived.
Author contribution statement
D B D conceived the study. D B D and V B S wrote the manuscript. G A, A C C and C F revised the manuscript. All authors reviewed and approved the final manuscript.
References
- 1↑
Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016 388 2783–2795. (https://doi.org/10.1016/S0140-6736(1630172-6)
- 2↑
NIH. Thyroid cancer. Cancer Stat Facts. (available at: https://seer.cancer.gov/statfacts/html/thyro.html)
- 3↑
Silva-Vieira M, Vaz SC, Esteves S, Ferreira TC, Limbert E, Salgado L, Leite V. Second primary cancer in patients with differentiated thyroid cancer: does radioiodine play a role? Thyroid 2017 27 1068–1076. (https://doi.org/10.1089/thy.2016.0655)
- 4↑
Lang BHH, Wong KP. Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma. Annals of Surgical Oncology 2011 18 3559–3565. (https://doi.org/10.1245/s10434-011-1777-1)
- 5↑
Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2008 93 504–515. (https://doi.org/10.1210/jc.2007-1154)
- 6↑
Lu CH, Lee KD, Chen PT, Chen CC, Kuan FC, Huang CE, Chen MF, Chen MC. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. European Journal of Endocrinology 2013 169 577–585. (https://doi.org/10.1530/EJE-13-0309).
- 7↑
Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, et al.Second primary cancers in thyroid cancer patients: a multinational record linkage study. Journal of Clinical Endocrinology and Metabolism 2006 91 1819–1825. (https://doi.org/10.1210/jc.2005-2009)
- 8↑
Endo M, Liu JB, Dougan M, Lee JS. Incidence of second malignancy in patients with papillary thyroid cancer from surveillance, epidemiology, and end Results 13 dataset. Journal of Thyroid Research 2018 2018 8765369. (https://doi.org/10.1155/2018/8765369)
- 9↑
Cho YY, Lim J, Oh CM, Ryu J, Jung KW, Chung JH, Won YJ, Kim SW. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer 2015 121 259–268. (https://doi.org/10.1002/cncr.29025)
- 10↑
Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. Second primary malignancies in thyroid cancer patients. British Journal of Cancer 2003 89 1638–1644. (https://doi.org/10.1038/sj.bjc.6601319)
- 11↑
Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, Liu CJ. Use of radioactive iodine for thyroid cancer and risk for second primary malignancy: a nationwide population-based study. Journal of the National Cancer Institute 2015 108 djv314. (https://doi.org/10.1093/jnci/djv314)
- 12↑
Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C. Incidence of nonthyroidal primary malignancy and the association with 131I treatment in patients with differentiated thyroid cancer. Thyroid 2016 26 1110–1116. (https://doi.org/10.1089/thy.2016.0037)
- 13↑
Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen PL. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. International Journal of Clinical Oncology 2016 21 231–239. (https://doi.org/10.1007/s10147-015-0904-6)
- 14↑
Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, Kang KW, Yi KH, Park DJ, Lee DS, et al.The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative 131I dose over 37 GBq. Clinical Endocrinology 2015 83 117–123. (https://doi.org/10.1111/cen.12581)
- 15↑
Murray SE, Schneider DF, Bauer PS, Sippel RS, Chen H. Synchronous and antecedent nonthyroidal malignancies in patients with papillary thyroid carcinoma. Journal of the American College of Surgeons 2013 216 1174–1180. (https://doi.org/10.1016/j.jamcollsurg.2013.02.007)
- 16↑
Lang BHH, Wong IOL, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 2012 151 844–850. (https://doi.org/10.1016/j.surg.2011.12.019)
- 17↑
Hirosawa RM, Marivo M, de Moura Leite Luengo J, Tagliarini JV, Castilho EC, de Alencar Marques A, Kiy Y, Marone MMS, Vaz de Arruda Silveira L, Ferreira da Silva Mazeto GM. Does radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm? ISRN Oncology 2011 2011 708343. (https://doi.org/10.5402/2011/708343)
- 18↑
Verkooijen RBT, Smit JWA, Romijn JA, Stokkel MPM. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. European Journal of Endocrinology 2006 155 801–806. (https://doi.org/10.1530/eje.1.02300)
- 19↑
Ömür O, Özcan Z, Yazici B, Akgün A, Oral A, Özkiliç H. Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome. Endocrine Journal 2008 55 365–372. (https://doi.org/10.1507/endocrj.k07e-058)
- 20↑
Cappagli V, Caldarella A, Manneschi G, Piaggi P, Bottici V, Agate L, Molinaro E, Bianchi F, Elisei R. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? International Journal of Cancer 2020 147 2838–2846. (https://doi.org/10.1002/ijc.33116)
- 21↑
Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, Haghpanah V. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clinical Nuclear Medicine 2011 36 277–282. (https://doi.org/10.1097/RLU.0b013e31820a9fe3)
- 22↑
Souza MC, Momesso DP, Vaisman F, Vieira Neto L, Aparecida RA, Corbo R, Vaisman M. Is radioactive iodine-131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer? Archives of Endocrinology and Metabolism 2016 60 9–15. (https://doi.org/10.1590/2359-3997000000078)
- 23↑
Marti JL, Jain KS, Morris LGT. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid 2015 25 681–687. (https://doi.org/10.1089/thy.2015.0067)
- 24↑
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph G, Sawka AM, Schlumberger M, et al.American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2015 26 1–133. (https://doi.org/10.1089/thy.2015.0020)
- 25↑
Gray RJ A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988 16 1141–1154. (https://doi.org/10.1214/aos/1176350951)
- 26↑
Costa Miranda A, Mayer-da-Silva A, Glória L, Brito C. Registo Oncológico Nacional DE TODOS OS TUMORES NA POPULAÇÃO RESIDENTE EM PORTUGAL, em 2018. Lisbon, Portugal: Reprografia do Instituto Português de Oncologia de Lisboa de Francisco Gentil - E.P.E, 2021. (available at: https://ron.min-saude.pt/media/2196/2021-0518_publica%C3%A7%C3%A3o-ron_2018.pdf)
- 27↑
Gandhi S, Abhyankar A, Basu S. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables. Nuclear Medicine Communications 2014 35 205–209. (https://doi.org/10.1097/MNM.0000000000000033)
- 28↑
Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Annals of Otology, Rhinology, and Laryngology 2006 115 607–610. (https://doi.org/10.1177/000348940611500806)
- 29↑
Ko KY, Kao CH, Lin CL, Huang WS, Yen RF. 131I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study. European Journal of Nuclear Medicine and Molecular Imaging 2015 42 1172–1178. (https://doi.org/10.1007/s00259-015-3055-0)
- 30↑
Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Sallé F, Mahoudeau J, et al.Risk of second primary cancer following differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 2004 31 685–691. (https://doi.org/10.1007/s00259-003-1448-y)
- 31↑
Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, et al.CHEK2 is a multiorgan cancer susceptibility gene. American Journal of Human Genetics 2004 75 1131–1135. (https://doi.org/10.1086/426403)
- 32↑
Giordano TJ Genomic hallmarks of thyroid neoplasia. Annual Review of Pathology-Mechanisms of Disease 2018 13 141–162. (https://doi.org/10.1146/annurev-pathol-121808-102139)
- 33↑
McTiernan A, Weiss NS, Daling JR. Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer. Cancer Research 1987 47 292–295
- 34↑
Bolf EL, Sprague BL, Carr FE. A linkage between thyroid and breast cancer: a common etiology? Cancer Epidemiology, Biomarkers and Prevention 2019 28 643–649. (https://doi.org/10.1158/1055-9965.EPI-18-0877)
- 35↑
da Silva Santos T, Tkachenko N, Couto de Carvalho A. Papillary thyroid cancer in a patient with germline CHEK2 mutation: a case report. Annales d’Endocrinologie 2021 82 624–626. (https://doi.org/10.1016/j.ando.2021.08.886)
- 36↑
Ikeda Y, Kiyotani K, Yew PY, Kato T, Tamura K, Yap KL, Nielsen SM, Mester JL, Eng C, Nakamura Y, et al.Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocrine-Related Cancer 2016 23 171–179. (https://doi.org/10.1530/ERC-15-0359)
- 37↑
Luo Y, Tsuchiya KD, il Park D, Fausel R, Kanngurn S, Welcsh P, Dzieciatkowski S, Wang J, Grady WM. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 2013 32 2037–2047. (https://doi.org/10.1038/onc.2012.225)
- 38↑
Dimitriou F, Mangana J, Curioni-Fontecedro A, Rechsteiner M, Turko P, Braun RP, Dummer R, Cheng PF. Melanoma patients with additional primary cancers: a single-center retrospective analysis. Oncotarget 2019 10 3373–3384. (https://doi.org/10.18632/oncotarget.26931)
